Emerging Nanomaterials and Nano-based Drug Delivery Approaches to Combat Antimicrobial Resistance (Micro and Nano Technologies) - Tapa blanda

Acerca de los autores

Dr. Muthupandian Saravanan is currently a Professor in the Department of Pharmacology at Saveetha University, SIMATS, Chennai, India. He has a degree in Microbiology from Madurai Kamaraj University and a Doctorate with Specialization in Medical Microbiology and Nanomedicine from Sathyabama University, India. As a Post-Doctoral Researcher at the Hebrew University of Jerusalem, he studied nano-biomaterials and their biomedical applications. He later worked as Associate Professor, under the United Nation Development Program in Department of Medical Microbiology and Immunology at Mekelle University in Ethiopia. He has published papers in high impact journals such as the Lancet and Nature. He has participated in more than 75 national and international conferences and reviewed of more than 100 international peer-reviewed journals. He has served as guest editor/ co-editor for reputed PubMed and Scopus indexed journals. He has received many fellowships and awards, notably the IET- Nanobiotechnology premium Awards in 2019 and 2020.

Hamed Barabadi (PharmD, PhD) works as an assistant professor at the Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. He received a PhD degree from Shahid Beheshti University of Medical Sci-ences, Tehran, Iran, in 2019. He graduated as a Doctor of Pharmacy (PharmD) from Mazandaran University of Medical Sciences, Sari, Iran, in 2014. He owns to his credit a number of research papers, book chapters, and edited books with more than 3000 citations and h-index of 38. He has received many awards such as IET―Nanobiotech¬nology Premium Awards two times continuously in the years 2019 and 2020. Dr. Barabadi has been featured among the World’s Top 2% scientists list, according to a Stanford University study 2020 and 2022. He is the guest editor/editor for various reputed indexed journals such as Current Nanomedicine, Nanoscience and Nanotechnology-Asia, Frontiers in Pharmacology, MDPI International Journal of Molecular Sciences, MDPI Molecules, and a few other prestigious journals. His research interests lie in the area of pharmaceutical nanobiotechnology, ranging from green synthesis, characterization, and optimization of nanobiomaterials to their pharmaceutical potential evaluations, such as anticancer, antimicrobial, antioxidant, etc. Moreover, he has collaborated actively with researchers in several other disciplines of pharmaceutical sciences, particularly the nanoformulation of drugs for drug delivery systems and nanomedicine.

Dr. Ebrahim Mostafavi has so far received training at Stanford University School of Medicine (PostDoc), Northeastern University (PhD), Harvard Medical School (Researcher), and University of Tehran (MSc and BSc). His research interests revolve around the engineering and development of (nano)biomaterials, nanocarriers, and 3D in vitro models (hydrogels, 3D bioprinted constructs, nanofibrous scaffolds, organoids, vascular grafts, and microfluidic systems) to create biologically complex systems for a range of applications such as cancer diagnostics and therapeutics, tissue engineering and regenerative medicine, biosensing, and infectious diseases. Dr. Mostafavi serves as an associate editor-in-chief of several prestigious and high-impact journals within Elsevier, Springer, Cell Press, Dove Medical Press, T&F, Frontiers, and so on He is also an editorial board member of more than 30 impactful and prestigious biomedical and materials science journals. His scholarly work comprises more than 200 publications with an H-index of 36 (i10-index of 105), including papers published in The Lancet family (i.e., Oncology, Infectious Diseases, Public Health, and Global Health) journals. So far, he has edited several books such as “Pharmaceutical Nanobiotechnology for Targeted Therapy” and “Emerging Nanomaterials and Nano-Based Drug Delivery Approaches to Combat Antimicrobial Resistance”. He has also contributed to leading more than 45 introductory book chapters in a very multidisciplinary field of bio/medical engineering, biotechnology, nanotechnology, materials science, and regenerative/ translational medicine.

Thomas J. Webster’s (H index: 107; Google Scholar) degrees are in chemical engineering from the University of Pittsburgh (B.S., 1995; USA) and in biomedical engineering from RPI (Ph.D., 2000; USA). He has served as a professor at Purdue (2000–2005), Brown (2005–2012), and Northeastern (2012–2021; serving as Chemical Engineering Department Chair from 2012–2019) Universities and has formed over a dozen companies who have numerous FDA approved medical products currently improving human health. He currently serves as a professor, biomedical engineering, Hebei University of Technology and Professor, Center for Biomaterials, Vellore Institute of Technology. Prof. Webster’s research explores the use of nanotechnology in numerous applications. Specifically, his research addresses the design, synthesis, and evaluation of nanophase materials (i.e., materials with fundamental length scales less than 100 nm) as more effective biomedical materials. He has directed numerous international centers in biomaterials and has graduated over 200 students with over 750 peer-reviewed publications. His research on nanomedicine has received attention in media including MSNBC, NBC Nightly News, PBS DragonFly TV, ABC Nightly News via the Ivanhoe Medical Breakthrough Segment, Fox News, the Weather Channel, NBC Today Show, NBC Nightly News, National Geographic TV series on the future of medicine, ABC Boston, Discovery Channel, and more. His work has been on display at the London and Boston Science Museums. He has helped to organize 27 conferences emphasizing nanotechnology in medicine and has organized over 83 symposia at numerous conferences emphasizing biological interactions with nanomaterials. Prof. Webster has received numerous honors including but not limited to: 2002, Biomedical Engineering Society Rita Schaffer Young Investigator Award; 2003, Outstanding Young Investigator Award Purdue University College of Engineering; 2005, American Association of Nanomedicine Young Investigator Award; 2005, Coulter Foundation Young Investigator Award; 2006, Fellow, American Association of Nanomedicine; 2010, Distinguished Lecturer in Nanomedicine, University of South Florida; 2011, Outstanding Leadership Award for the Biomedical Engineering Society (BMES); 2012, Fellow, American Institute for Medical and Biological Engineering (AIMBE, representing the top 2% of all medical and biological engineers); 2013, Fellow, Biomedical Engineering Society; 2014, Fellow, Ernst Strugmann; 2016, Fellow, College of Fellows of the International Union of Biomaterials Sciences and Engineering; 2016, Wenzhou 580 Award; 2016, Zeijiang 1000 Talent Program; 2016, SCOPUS Highly Cited Research (Top 1% Materials Science); 2016, Hsun Chinese Academy of Sciences Award; 2017, Fellow, National Associate of Inventors; 2017, Acta Biomaterialia Silver Award (given to researchers under the age of 45); 2019, Overseas Fellow, Royal Society for Medicine; 2020, World Top 2% Scientist by Citations (PLOS); 2020, SCOPUS Highly Cited Research (Top 1% Mixed Fields); and others.

De la contraportada

Antimicrobial resistance threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses, and fungi. Antimicrobial resistance occurs when bacteria, viruses, fungi, and parasites change over time and no longer respond to medicines making infections harder to treat and increasing the risk of disease spread, severe illness, and death. As a result, the medicines become ineffective, and infections persist in the body, increasing the risk of spread to others. Antimicrobials, including antibiotics, antivirals, antifungals, and antiparasitics, are medicines used to prevent and treat infections in humans and animals. Microorganisms that develop antimicrobial resistance are sometimes referred to as "superbugs". Nanomaterials can overcome the antibiotic-resistance mechanisms owing to their unique physicochemical properties, enabling nanomaterials to execute multiple novel microbicidal pathways to achieve antimicrobial activity. Nanomaterials can bind and disrupt bacterial membranes, causing leakage of cytoplasmic components. Nanomaterials have emerged as new tools that can be used to combat deadly microbial infections.

This book focuses on the recent emerging trends on nanomaterials and nano-drug delivery approaches to combat antimicrobial resistance. The relationship between the nanomaterials, antimicrobial activity is needed to be deeply explored to meet the abiding challenges to combat the antimicrobial resistance. The content of this book is divided into three main topic areas including (i) how to overcome the existing traditional approaches to combat antimicrobial resistance (ii) applying multiple drug delivery mechanisms to target multi-drug resistant microbes (iii) how the nanomaterials can be used as drug carriers.

This is an important reference source for those looking to understand how nanotechnology plays an important role in combatting disease and infection.